Neuro-Eye Clinical Trials

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Graves' disease and hyperthyroidism8 trials
• Multiple sclerosis1 trial

Phase

• Phase 38 trials
• Phase 41 trial

Status

• Completed4 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Viridian Therapeutics, Inc.8 trials
• Oculis1 trial

Running trials

• Not yet recruiting

  An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab

  NCT07832136· Phase 4· Viridian Therapeutics, Inc.· Source

  Contact: Study Coordinator

• Recruiting

  Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

  NCT07623668· Phase 3· Oculis· Source

  Contact: Mirna Maldonado

• Active, not recruiting

  A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

  NCT06812325· Phase 3· Viridian Therapeutics, Inc.· Source

• Active, not recruiting

  An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06625398· Phase 3· Viridian Therapeutics, Inc.· Source

• Active, not recruiting

  An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

  NCT06625411· Phase 3· Viridian Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Graves' disease and hyperthyroidism1 recruiting
• Multiple sclerosis1 recruiting

Closed trials

• Completed

  A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

  NCT06384547· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

  NCT06179875· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06021054· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

  NCT05176639· Phase 3· Viridian Therapeutics, Inc.· Source